Merck acquires Peloton Therapeutics for $1 billion
The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 21, 2019 Category: Pharmaceuticals Source Type: news

Mesothelioma Clinical Trial Exploring Family Predisposition
The National Cancer Institute has opened a clinical trial using mesothelioma patients and their family members to explore predisposition to the cancer and potential solutions to negating it. The trial is a follow up to an earlier study of a genetic mutation that creates susceptibility to various cancers but a longer-than-normal survival with platinum-based chemotherapy treatment. “This is an important, long-term study that could have implications not only for a patient, but for family members, too,” Dr. Raffit Hassan, NCI senior investigator told The Mesothelioma Center at Asbestos.com. “Progress can be m...
Source: Asbestos and Mesothelioma News - May 20, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2019 Category: International Medicine & Public Health Source Type: news

Avelumab & #43; Axitinib Approved for Treatment of Renal Cell Carcinoma
THURSDAY, May 16, 2019 -- Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced. The agency based the approval on data... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news

FDA approves avelumab plus axitinib for renal cell carcinoma
On May 14, 2019, the Food and Drug Administration approved avelumab (BAVENCIO ®, EMD Serono, Inc.) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals
The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

FDA Okays Another Immunotherapy Plus TKI for Advanced RCC FDA Okays Another Immunotherapy Plus TKI for Advanced RCC
The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 15, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA
Approval marks the first anti-PD-L1 therapy combination for RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news

Intraperitoneal vs IV Chemotherapy in Ovarian Cancer: How Do They Compare?
A trial compared two intraperitoneal chemotherapy regimens and an intravenous regimen for newly diagnosed advanced ovarian carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019– Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2019 Category: Drugs & Pharmacology Source Type: news

Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 13, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Biomarker-Driven Drug for HCC FDA Approves First Biomarker-Driven Drug for HCC
Ramucirumab is for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level of 400 ng/mL or higher.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 13, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Nail technicians are up to '100 TIMES more at risk of cancer'
A study of six nail salons in Colorado found their air contained formaldehyde at levels beyond what is deemed safe to avoid squamous cell carcinoma, nasopharyngeal cancer or Hodgkin's lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - May 13, 2019 Category: Consumer Health News Source Type: news

MR imaging evaluation of hepatocellular carcinoma treated with SBRT
(American Roentgen Ray Society) Although arterial phase hyperenhancement (APHE) is a key feature of untreated or recurrent hepatocellular carcinoma (HCC), standard response assessment such as modified Response Evaluation Criteria in Solid Tumors (mRECIST) should be used with caution, particularly in the early phases after stereotactic body radiation therapy (SBRT) therapy, so as not to misinterpret treatment response, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10, 2019 in Honolulu, Hawaii. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 9, 2019 Category: Cancer & Oncology Source Type: news

Iowa Army veteran, 20, marries his girlfriend hours before dying of rare liver cancer
US Army National Guard veteran Tristin Laue, 20, from Waverly, Iowa, died of fibrolamellar carcinoma, a rare form of liver cancer, on April 27, just five hours after he married girlfriend Tianna Hargrafen. (Source: the Mail online | Health)
Source: the Mail online | Health - May 8, 2019 Category: Consumer Health News Source Type: news

Percutaneous Ablation in Liver Cancer Tied to Better Outcomes
WEDNESDAY, May 8, 2019 -- For patients with hepatocellular carcinoma (HCC), percutaneous liver ablation interventions are associated with lower in-hospital mortality, length of stay (LOS), and hospitalization costs compared with surgical procedures,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2019 Category: Pharmaceuticals Source Type: news

Mutation Profiles May Aid in Treatment of Non –Clear-Cell Renal Cell Carcinoma
Analyzing somatic and germline mutations and MSI may reveal clinically actionable mutations in a proportion of patients with advanced RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

Estate agent, 40, is left with a deformed lip after years of tanning left her with a cancerous lump
WARNING, GRAPHIC CONTENT: Kory Feltz, from California, had sunbathed from the age of 13 until she was blistered and burnt. She developed a squamous cell carcinoma on her lip. (Source: the Mail online | Health)
Source: the Mail online | Health - May 3, 2019 Category: Consumer Health News Source Type: news

Efficacy of One-Day Fractionated Photodynamic Therapy for Basal Cell Carcinoma
Researchers evaluated the response of patients with BCC to fractionated photodynamic therapy at 30 days after treatment. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Review Touts Benefits of Immunotherapy for Non-Melanoma Skin Cancers
The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers. (Source: CancerNetwork)
Source: CancerNetwork - May 3, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Changes in the metabolism of normal cells promotes the metastasis of ovarian cancer cells
(University of Chicago Medical Center) A systematic examination of the tumor and the tissue surrounding it -- particularly normal cells in that tissue, called fibroblasts -- has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a tumor type that primarily originates in the fallopian tubes or ovaries and spreads throughout the abdominal cavity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2019 Category: Cancer & Oncology Source Type: news

Sebaceous Carcinoma of the Nose Sebaceous Carcinoma of the Nose
In this case, a presentation of sebaceous carcinoma in an uncommon anatomical location is discussed. Find out about the diagnostic and treatment options for this rare type of cancer.ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 30, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Metformin and Survival in Hepatocellular Carcinoma Metformin and Survival in Hepatocellular Carcinoma
How might treatment with metformin influence survival in patients with hepatocellular carcinoma and T2DM?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 29, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma
Dr. Balar highlights promising evidence on the potential benefits of the use of immunotherapy in the advanced bladder cancer setting. (Source: CancerNetwork)
Source: CancerNetwork - April 29, 2019 Category: Cancer & Oncology Authors: Arjun V. Balar, MD Source Type: news

Heavier and taller children are more likely to develop kidney cancer as adults than their average-sized peers
(European Association for the Study of Obesity) A study of more than 300,000 individuals in Denmark, presented at this year's European Congress on Obesity in Glasgow, Scotland (April 28-May 1), reveals that heavier and taller children are at greater risk than their average-sized peers of developing the kidney cancer renal cell carcinoma (RCC) as adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2019 Category: International Medicine & Public Health Source Type: news

Basal Cell Carcinoma Subtype Reporting Varies by Practice, May Put Patients at Risk Basal Cell Carcinoma Subtype Reporting Varies by Practice, May Put Patients at Risk
Underreporting of basal cell carcinoma (BCC) subtypes occurs in academic, teaching and nonteaching institutions and may place patients at risk for inadequate or inappropriate therapy, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Six Factors Tied to DCIS Returning as Breast Cancer Six Factors Tied to DCIS Returning as Breast Cancer
A group of six factors are associated with ductal carcinoma in situ returning as invasive breast cancer after treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Six Prognostic Factors ID'd for Invasive Disease After DCIS
THURSDAY, April 25, 2019 -- In a review published online April 25 in Cancer Epidemiology, Biomarkers& Prevention, six prognostic factors are identified that may predict invasive disease after a diagnosis of ductal carcinoma in situ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2019 Category: Pharmaceuticals Source Type: news

Six factors may predict invasive breast cancer recurrence after DCIS diagnosis
(American Association for Cancer Research) Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Ramsey Awarded ACS, NCI Research Grants for Skin Cancer Studies
Matthew Ramsey, PhD, of the Department of Dermatology, was selected for a 2019 Research Scholar Grant by the American Cancer Society (ACS) in support of his work on Basonuclin 1 in Squamous Cell Carcinoma (SCC).Ramsey also received a two-year, $403,0 (Source: BWH News)
Source: BWH News - April 24, 2019 Category: Hospital Management Source Type: news

FDA Approves Pembrolizumab Plus Axitinib for Advanced RCC
TUESDAY, April 23, 2019 -- The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday. The agency approved the drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2019 Category: Pharmaceuticals Source Type: news

Keytruda, Pfizer combo gets FDA ok for advanced kidney cancer
The U.S. FDA approved Merck's blockbuster Keytruda in combination with Pfizer's Inlyta as a first-line treatment for advanced renal call carcinoma — kidney cancer that has spread, despite earlier treatments. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 22, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Inlyta (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
KENILWORTH, N.J.--(BUSINESS WIRE)--April 22, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 22, 2019 Category: Drugs & Pharmacology Source Type: news

Mauritian medical herbs possess antitumor properties
(Far Eastern Federal University) Far Eastern Federal University (FEFU) scientists teamed up with colleagues from the UK and Mauritius and experimentally demonstrated that extracts of the endemic (i.e. growing only on this island) medicinal herb leaves Acalypha integrifolia, Eugenia tinifolia, and Labourdonnaisia glauca stop the proliferation of esophageal squamous carcinoma cells, ones of the most deadly cancer type worldwide. A related article is published in the Acta Naturae journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2019 Category: Cancer & Oncology Source Type: news

BALVERSA ™ (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations
(Source: Johnson and Johnson)
Source: Johnson and Johnson - April 15, 2019 Category: Pharmaceuticals Source Type: news

Protective Effects of Coffee Post- Liver Transplant for HCC Protective Effects of Coffee Post- Liver Transplant for HCC
Does coffee consumption reduce the risk of hepatocellular carcinoma recurrence after liver transplantation?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

OCT for Diagnosis of Basal Cell Carcinoma OCT for Diagnosis of Basal Cell Carcinoma
This review explores how optical coherence tomography, a noninvasive near-infrared light imaging technology, might improve the diagnosis and management of basal cell carcinoma.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

New class of medicines shows promise
'Gene silencing' spares patients the crippling pain of intermittent porphyria Related items fromOnMedica Higher cancer risk from chronic diseases Hepatocellular carcinoma risk, cirrhosis and hepatitis C Kidney disease hits 850 million people Commonest genetic mutation causes much morbidity Prevention screening for one third of population (Source: OnMedica Latest News)
Source: OnMedica Latest News - April 15, 2019 Category: UK Health Source Type: news

Endoscopic Surveillance Finds Unsuspected Carcinomas in Predisposed Individuals Endoscopic Surveillance Finds Unsuspected Carcinomas in Predisposed Individuals
Endoscopic surveillance can identify unsuspected signet-ring-cell carcinoma in individuals predisposed to hereditary diffuse gastric cancer (HDGC) by virtue of pathogenic variants in CDH1, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 11, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Aldo-keto reductase family 1 member B10 predicts advanced nonalcoholic steatohepatitis
(Kanazawa University) AKR1B10 is a useful serum biomarker for advanced liver fibrosis in Nonalcoholic steatohepatitis and, combined with serum WFA(+)-M2BP, it can predict hepatocellular carcinoma development, gastroesophageal varix formation, and poor prognosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 11, 2019 Category: International Medicine & Public Health Source Type: news

Cutaneous Metastasis of Urothelial Carcinoma of the Bladder Cutaneous Metastasis of Urothelial Carcinoma of the Bladder
This case details rare cutaneous metastatic disease arising from urinary tract carcinoma.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

TGen review links gene with the most common liver cancer
(The Translational Genomics Research Institute) In an article published in the scientific journal Cancers, researchers at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, provide the first summary of the experimental evidence supporting the AKR1B10 enzyme as a promising therapeutic target for Hepatocellular carcinoma (HCC), based on a review of more than 50 studies published since this gene was first identified and characterized in 1998. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2019 Category: Cancer & Oncology Source Type: news

Mayo Clinic Minute: 3 types of skin cancer
There's no questions that sun exposure increases your risk of skin cancer. ?Skin cancer is the most common type of cancer in the U.S., according to the Centers for Disease Control and Prevention.?Dr. Dawn Davis, a Mayo Clinic dermatologist, says there are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 8, 2019 Category: Databases & Libraries Source Type: news

Precursor Immunotherapy to Prevent Squamous Cell Carcinoma
Researchers evaluated whether  treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Cabozanitinib Shows Anti-Tumor Activity Beyond Clear-Cell Renal Cell Carcinoma
A recent study inThe Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Researchers discover why men are more likely to develop liver cancer
(Rockefeller University Press) Researchers in Spain have discovered that a hormone secreted by fat cells that is present at higher levels in women can stop liver cells from becoming cancerous. The study, which will be published April 3 in the Journal of Experimental Medicine, helps explain why hepatocellular carcinoma (HCC) is more common in men, and could lead to new treatments for the disease, which is the fourth leading cause of cancer-related death worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 3, 2019 Category: Cancer & Oncology Source Type: news

Adiponectin, the hormone that protects women against liver cancer
(Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.)) The study, published in the Journal of Experimental Medicine, shows that adiponectin protects the liver against the development of the main form of liver cancer, hepatocellular carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 3, 2019 Category: Cancer & Oncology Source Type: news

DART: Success Story in High-Grade Neuroendocrine Carcinomas DART: Success Story in High-Grade Neuroendocrine Carcinomas
Patients with high-grade neuroendocrine carcinomas benefit from dual checkpoint inhibition with ipilimumab and nivolumab after single-agent checkpoint inhibition has failed. Is dual checkpoint blockade ready for prime time?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Exosomes from Blood Carry RNA Signatures of Liver Cancer
A small study finds that the tiny extracellular vesicles from patients with hepatocellular carcinoma have RNA content distinct from patients with cirrhosis only. (Source: The Scientist)
Source: The Scientist - April 2, 2019 Category: Science Tags: News & Opinion Source Type: news